Research shows subopitmal reporting of adverse events in targeted therapy and immunotherapy trials

A significant number of trials of targeted therapies and immunotherapies in recent years show suboptimal reporting of adverse events, particularly the reporting of recurrent or late toxicities and the duration of the adverse events, researchers have told the ESMO 2016 Congress in Copenhagen. “Reporting adverse events from clinical trials with new agents is a crucial …

Research shows subopitmal reporting of adverse events in targeted therapy and immunotherapy trials Read More »